Core Viewpoint - OSE Immunotherapeutics, Inserm Transfert, and Nantes University have formed a strategic partnership to accelerate innovation in immunotherapy, focusing on oncology, inflammation, and autoimmunity [1][2]. Group 1: Partnership Objectives - The partnership aims to combine academic research with industrial expertise to transform immunology discoveries into industrial programs that can deliver breakthrough therapies to patients [2]. - The collaboration will unite scientific teams and pool expertise to develop innovative projects into programs ready for industrial development [3]. Group 2: Project Development - Inserm Transfert and Nantes University will lead the project identification process, allowing OSE Immunotherapeutics to access promising programs from their research units [3]. - Selected projects will receive financial support and dedicated guidance to facilitate their development [3]. Group 3: Leadership Insights - Pascale Augé from Inserm Transfert emphasized the importance of public-private partnerships in healthcare and the commitment to supporting research excellence [4]. - Frédéric Jacquemin from Nantes University highlighted the role of collaborative research in driving therapeutic innovation [4]. - Nicolas Poirier from OSE Immunotherapeutics expressed enthusiasm for the collaboration, noting its potential to enhance immunological innovation across France [4]. Group 4: Organizational Background - Inserm Transfert is a private subsidiary of Inserm focused on development and innovation in human health, managing the entire innovation value chain from research to industry [5]. - Nantes University is recognized for its excellence in health research and innovation, contributing to the collaborative research and technology transfer efforts [6][7]. - OSE Immunotherapeutics specializes in developing first-in-class assets in immuno-oncology and immuno-inflammation, partnering with academic institutions and biopharmaceutical companies [8].